Ascletis to present ASC47 obesity data at ECO 2025

Ascletis Pharma Inc. (HKEX:1672) announced that it will present preliminary study results for ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate, at the European Congress on Obesity (ECO) in Malaga, Spain in May 2025. The presentations will cover both oral and poster sessions, showcasing the potential of ASC47 in obesity treatment. The oral presentation will highlight significant weight loss and muscle preservation in preclinical models, while the poster presentation will discuss a first-in-human, single ascending dose study in healthy participants. Ascletis has U.S. FDA clearance for an Investigational New Drug application for ASC47 in combination with semaglutide for obesity.